NEW OPPORTUNITIES IN TREATMENT OF JUVENILE ANKYLOSING SPONDYLOARTHRITIS
Abstract
Development of effective and safe methods of treatment of juvenile ankylosing spondyloarthritis is one of topical problems of modern rheumatology. At the same time, the number of antirheumatic drugs used for the treatment of this disease is limited. It is necessary to widen a range of immunosuppressive medications for inclusion of genetically engineered biological agents. The objective of performed open-labeled trial was effectiveness and safety of monoclonal antibodies to tumor necrotizing factor (TNF) _ — infliximab. The study included 107 patients with juvenile ankylosing spondyloarthritis. 58 children were treated with infliximab, and 49 — with sulfasalazine. Duration of treatment was 54 weeks. In the end of a study 42% of patients treated with infliximab had status of inactive disease, and only 2% of patients in sulfasalazine group had the same status.
Key words: children, juvenile ankylosing spondyloarthritis, infliximab, sulfasalazine, treatment.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(2):23-31)
About the Authors
E.I. AlexeevaA.L. Kozlova
S.I. Valiyeva
T.M. Bzarova
A.M. Chomakhidze
K.B. Isaeva
References
1. Козлова А.Л., Алексеева Е.И., Валиева С.И. и др. Эффективность инфликсимаба у больных ювенильным анкилозирующим спондилоартритом. Вопросы современной педиатрии. 2009; 8 (2): 20–27.
2. Бочкова А.Г. Анкилозирующий спондилит. М.: Институт ревматологии РАМН. 2005. С. 3–26.
3. Никишина И.П. Ювенильный анкилозирующий спондилоартрит. Практическое руководство по детским болезням. Том III. Под общей ред. В. Ф. Коколиной, А. Г. Румянцева. М.: Медпрактика. 2004. С. 620–649.
4. Кузьмина Н.Н. Ювенильный анкилозирующий спондилоартрит. Детская ревматология: Руководство для врачей. Под ред. А.А. Баранова, Л.К. Баженовой. М.: Медицина. 2002.
5. С. 141–182.
6. Марканова А.М., Шахбазян И.Е., Алексеева Е.И. Эффективность сульфасалазина и низких доз метотрексата у детей, страдающих олигоартикулярным вариантом ювенильного ревматоидного артрита. Российский педиатрический журнал. 2001; 4: 34–37.
7. Nissila M., Lehtinen K., Leirisalo-Repo M. et al. Sulphasazine in the treatment of ankylosing spondilitis: a twenty-six-week placebocontrolled clinical trial. Arth. Rheum. 1998. 31. P. 1111–1116.
8. Алексеева Е. И., Литвицкий П. Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. М.: Веди. 2007. 236 с.
9. Fearon U., Veale D. J. Pathogenesis of psoriatic arthritis. Clin. Exp. Dermatol. 2001; 26: 333–337.
10. Kalden J. R. Emerging role of anti–tumor necrosis factor therapy in rheumatic diseases. Arthritis Res. 2002; 4 (Suppl. 2): 534–540.
11. Mease P., Kivitz A. J., Burch F. X. et al. Etanercept treatment of psoriatic arthritis: sarety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50: 2264–2272.
12. Beutler B. A. The role of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (Suppl. 57): 16–21.
13. Granfors K., Marker-Hermann E., De Kayser F. The cutting edge of spondiloarthropathy research in the millennium. Arthritis Rheum. 2002; 46 (3): 606–613.
14. Mease P., Antoni C. E. Psoriatic arthritis treatment: biological response modifiers. Ann. Rheum. Dis. 2005; 64 (Suppl. 2): 78–82.
15. Бадокин В. C. Эффективность ингибиторов биологического ответа при псориатическом артрите. Врач. 2005. 5. С. 48–52.
16. Reed M. R., Taylor A. L. Tumor necrosis factor inhibitors in ankylosing spondylitis. Intern. Med. J. 2008; 38 (10): 781–789.
17. Haibel H., Song I. H., Rudwaleit M. et al. Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 week in daily practice. Clin. Exp. Rheumatol. 2008; 26 (2): 247–252.
18. Braun J., Deodhar A., Dijkmans B. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 2008; 59 (9): 1270–1278.
19. Griffoul I., Giraudeau B., Mulleman D. et al. Infliximab for treating axial spondylarthropathy in everyday practice. Joint Bone Spine. 2009; 76 (1): 39–43.
20. Румянцева О. А. Исследование эффективности, безопасности и переносимости инфликсимаба у больных анкилозирующим спондилитом (предварительные результаты). Научно-практическая ревматология. 2006; 4: 11–19.
21. Preur A. M., Dougados M., Listrat V., Amor B. Evaluation of four sets of criteria for spondyloarthropathy in children: a multicenter cross-sectional European study. Arthritis Rhem. 1992; 35 (Suppl.): 190.
22. Ruperto N., Lovell D. J., Quartier P. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008; 372 (9636): 383–391.
23. Wallace C. A., Ruperto N., Gannini E. et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J. Rheumatol. 2004; 31 (11): 2290–2294.
Review
For citations:
Alexeeva E., Kozlova A., Valiyeva S., Bzarova T., Chomakhidze A., Isaeva K. NEW OPPORTUNITIES IN TREATMENT OF JUVENILE ANKYLOSING SPONDYLOARTHRITIS. Current Pediatrics. 2010;9(2):23-31.
Email this article 
